

Neu-Ulm / Berlin, 01 April 2019

The NUVISAN group continues steady growth by acquiring STRATEC Molecular GmbH

On April 1, the majority shareholder of the NUVISAN Group announced the acquisition of INVITEK Molecular GmbH (formerly STRATEC Molecular GmbH).

The newly founded company will be part of the NUVISAN group from 01.04.2019. To underline its commitment to developing and commercializing innovative and high-quality nucleic acid purification solutions, the company has been renamed INVITEK Molecular GmbH.

At the Berlin location, the company will focus on the areas of oncology, infectious disease and microbiome research, and operate as system and OEM partner for leading in-vitro diagnostics companies. In the future, the Berlin-based company plans to concentrate on emerging molecular diagnostics applications such as liquid biopsy.

NUVISAN thus underscores its claim to becoming Europe's leading one-stop pharma services provider in the field of early stage drug development for the pharmaceutical industry with its fourth acquisition since 2011. With INVITEK Molecular products NUVISAN now completes their ability to offer innovative system solutions for DNA and RNA sample preparation used in molecular diagnostics, drug discovery, and life science research with desired synergistic effects for all NUVISAN business units.

About NUVISAN GmbH

The NUVISAN group generates sales of approx. € 40 million and an EBITDA margin of > 15% with currently about 380 highly qualified employees. It originated from LAB GmbH 40 years ago and has been operating under the name NUVISAN with its headquarters in Neu-Ulm since 2010. The NUVISAN group as a Clinical Research Organization (CRO) has five sites (Neu-Ulm, Berlin, Grafing, Waltrop/ Germany and Sophia-Antipolis/ France) and sales offices in LATAM America and in the USA.

Press Contact

Elmar Rothenfusser
NUVISAN GmbH

Tel.: +49 731 9840 143
Wegenerstr. 13

Email: elmar.rothenfusser@nuvisan.com
D-89321 Neu-Ulm